Expert Insights


Hope for Patients With Metastatic Breast Cancer

For 74% of patients who have metastatic breast cancer, the disease is fatal within five years. Comprehensive genomic profiling (CGP) quickly identifies actionable alterations that can inform breast cancer treatment options. Therapies that ...

Progression Free Survival After Liquid Biopsy Similar to Rates After Tissue

As liquid biopsy continues to gain recognition as an invaluable clinical tool in the treatment of all metastatic solid tumors, this blood-first approach is being recommended more and more often in treatment guidelines, including those ...

Advanced Solid Tumor Patients Deserve a Blood-First Paradigm

Not all oncology patients with actionable biomarkers are being identified, subjecting these patients to suboptimal treatment. But scientific advances have transformed the diagnostic landscape; when oncologists initiate ...

KRAS G12C Now Actionable With New FDA-Approved Therapy

Forty-five percent of patients with non-small cell lung cancer (NSCLC) now have actionable driver mutations. KRAS is the most frequently-mutated oncogene in human cancers, and of all KRAS driver-mutations, KRAS G12C is the most ...

A New Standard of Care

Targeted cancer therapies are prolonging patient survival times and improving quality of life, outcomes which are facilitated by tumor mutation profiling. Because cancer genomes are complex, comprehensive genomic profiling ...

Precise and Rapid Advanced Cancer Treatment Selection

For patients diagnosed with late-stage cancer, the longer treatment is delayed, the poorer the clinical prognosis, yet capturing a comprehensive picture of the disease is essential for determining the most appropriate first-line treatment ...